TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.
Recce Pharmaceuticals Ltd announced the dispatch of documents related to its 2025 Annual General Meeting to shareholders. The company’s innovative anti-infective solutions, which have garnered significant recognition, position it as a key player in addressing global health challenges related to antibiotic resistance. The upcoming meeting is set to discuss these advancements and their implications for stakeholders.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company focused on developing a new class of synthetic anti-infectives aimed at tackling antibiotic-resistant superbugs. Their product pipeline includes patented, broad-spectrum synthetic polymer anti-infectives such as RECCE 327 for serious bacterial infections, RECCE 435 for oral bacterial infections, and RECCE 529 for viral infections. The company has received recognition from the World Health Organization and the FDA for its efforts in combating antimicrobial resistance.
Average Trading Volume: 113,899
Technical Sentiment Signal: Hold
Current Market Cap: A$120M
See more data about RCE stock on TipRanks’ Stock Analysis page.